References

Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure−activity relationships

10.1021/jm011107f · 2002 · External reference

Unresolved reference

2019 · External reference

Sugammadex reversal of muscle relaxant blockade provided less post-anesthesia care unit adverse effects than neostigmine/glycopyrrolate

10.1016/j.jfma.2022.04.017 · 2022 · External reference

Sugammadex hypersensitivity: a multicentre retrospective analysis of a large Australian cohort

10.1016/j.bja.2024.07.042 · 2024 · External reference

Sugammadex: a scientific review including safety and efficacy, update on regulatory issues, and clinical use in Europe

10.1097/mjt.0000000000000092 · 2015 · External reference

Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine

10.1097/aln.0b013e31818a3fee · 2008 · External reference

Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects

10.5414/cp201976 · 2014 · External reference

Sugammadex provides faster reversal of vecuroniuminduced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial

10.1213/ane.0b013e3181ac53c3 · 2010 · External reference

Efficacy and safety of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in patients with end-stage renal disease: a systematic review and meta-analysis

10.3390/medicina57111259 · 2021 · External reference

Unresolved reference

2016 · External reference

Sugammadex

10.36303/sajaa.2020.26.6.s3.2555 · 2020 · External reference

Sugammadex: a revolutionary drug in neuromuscular pharmacology

10.4103/0259-1162.123211 · 2013 · External reference

Comparison between sugammadex and neostigmine after video-assisted thoracoscopic surgery–thymectomy in patients with myasthenia gravis: a single-center retrospective exploratory analysis

10.3390/jpm13091380 · 2023 · External reference

Sugammadex administration in patients with end-stage renal disease: a narrative review with recommendations

10.17085/apm.22259 · 2023 · External reference

Efficacy, safety and pharmacokinetics of sugammadex 4 mg kg-1 for reversal of deep neuromuscular blockade in patients with severe renal impairment

10.1093/bja/aet586 · 2015 · External reference

An appraisal of neostigmine versus sugammadex for neuromuscular blockade reversal in patients with a prior heart transplant

10.5114/ait.2023.125337 · 2023 · External reference

Reversal of neuromuscular block

10.1093/bja/aep093 · 2009 · External reference

Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function

10.1093/bja/aen216 · 2008 · External reference

Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study

10.1093/bja/aep340 · 2010 · External reference

Review on uremic toxins: classification, concentration, and interindividual variability

10.1046/j.1523-1755.2003.00924.x · 2003 · External reference

Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent

10.2147/dddt.s2757 · 2008 · External reference